Research programme: ubiquitin-modifying therapeutics - Boehringer Ingelheim/Mount Sinai Hospital/University Health Network/University of Toronto

Drug Profile

Research programme: ubiquitin-modifying therapeutics - Boehringer Ingelheim/Mount Sinai Hospital/University Health Network/University of Toronto

Alternative Names: Ubiquitin-binding variants - Boehringer Ingelheim

Latest Information Update: 12 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Mount Sinai Hospital (Toronto); University Health Network; University of Toronto
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; CNS disorders; Diabetes mellitus; Inflammation

Most Recent Events

  • 22 Jul 2014 Boehringer Ingelheim forms a research alliance with the University of Toronto, University Health Network and Mount Sinai Hospital
  • 22 Jul 2014 Early research in Cancer in Canada (unspecified route)
  • 22 Jul 2014 Early research in CNS disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top